Understand FDA changes in terms of your exact products.

Product-level FDA monitoring, delivered to your inbox. Which of your products are affected — by name and ingredient — with the analysis and action items already written.

From: Policy Canary <alerts@policycanary.io>

Your Marine Collagen Powder — Action Required

March 4, 2026 · 7:14 AM

Urgent · Action Required

Marine Collagen Powder

The FDA cited three companies for identity-testing failures on marine-sourced collagen in the last 90 days. Your product's ingredient profile matches the cited substances. Lab protocols need updating.

Action Items

  1. Verify identity-testing protocols for marine collagen
  2. Request updated CoA from supplier
  3. Document compliance review for FDA inspection readiness

Deadline

Q2 2026

Source

21 CFR 111.75(a)(1)(ii)

THE DIFFERENCE

Every FDA action.
Matched to your products.

Not summaries — product intelligence. Each card shows what Policy Canary actually delivers to your inbox.

Email Intelligence

Intelligence delivered, not searched for

Every alert arrives in your inbox, scoped to your products — with the analysis and action items already written.

From: Policy Canary

Your Marine Collagen Powder — Action Required

Marine Collagen Powder

Identity-testing warning mapped to your ingredient profile.

Action required by Q2 2026

21 CFR 111.75(a)(1)(ii)

Ingredient Match

Matched by formula

We match FDA actions to your actual ingredients — not just product categories.

Marine Collagen Powder
Vitamin D3Marine CollagenHyaluronic Acid

Matched to FDA Warning Letter WL-2025-1847

Speed

FDA to inbox in hours

Our pipeline ingests every publication the same day.

FDA publishes

Oct 14

Pipeline ingests

Oct 14

Your inbox

<24h

Dashboard

Every product at a glance

One view. All your products. Color-coded status.

Monitored Products

Marine Collagen Powder

BHA Eye Cream SPF 15

Biotin Complex 5000mcg

Coverage

7 FDA data sources

Federal Register, guidance documents, warning letters, import alerts, Regulations.gov, openFDA, and RSS — all in one pipeline.

Federal Register

847

Warning Letters

1,247

openFDA

169K

Guidance Docs

2,761

Import Alerts

154

Regulations.gov

1,178

RSS Feeds

12

WHEN YOU NEED TO DIG DEEPER

Your dashboard is herewhen you need it.

The intelligence starts in your inbox. When you want to explore further — search enforcement history, manage products, see the full picture — your dashboard is ready.

app.policycanary.com/products

Monitored Products

Intelligence Report2h ago

Marine Collagen Powder

21 CFR 111.75(a)(1)(ii)

NovaBiotics failed identity testing for marine collagen. COA-only documentation was deemed insufficient by the FDA. Your product uses the same ingredient — this warning applies to your formulation.

Recommended Actions

  • 1Audit identity testing protocols against 21 CFR 111.75(a)(1)(ii)
  • 2Verify COA includes marine collagen-specific identity tests, not generic protein analysis
  • 3Confirm per-batch testing with your contract manufacturer

Action required by Q2 2026

Source: FDA CFSAN Warning Letters · 21 CFR 111.75(a)(1)(ii)

Interactive demo · click any product to see its intelligence

WEEKLY INTELLIGENCE

The FDA This Week

Oct 5–Oct 9, 2026

The FDA executed a significant administrative purge of the generic drug market this week, withdrawing approval for 53 abbreviated new drug applications from manufacturers including Par Health USA and Amneal Pharmaceuticals. Food sector focus shifted to traceability compliance with new draft guidance on enforcement policies for retail establishments and restaurants regarding FSMA recordkeeping. Parallel enforcement in the supplement and device categories addressed acute safety risks, specifically banned DMAA in pre-workout powders and particulate matter in ICU Medical IV tubing.

0items tracked
0sectors active
0substances flagged
0deadlines identified
Pharma8Food6Devices5Biologics2Supplements2

Par Health USA LLC, U.S. Agent for PH Health Limited, et al.; Withdrawal of Approval of 37 Abbreviated New Drug Applications

FDA is withdrawing approval of 37 Abbreviated New Drug Applications (ANDAs) held by Par Health USA LLC and other entities. This administrative action removes the legal authorization to market these generic drug products in the United States.

Generic DrugsPrescription Drugs
Draft GuidanceDue 2026-11-23

Guidance for Industry: Requirements for Additional Traceability Records for Certain Foods: Enforcement Policy for Certain Retail Food Establishments and Restaurants

The FDA's Human Foods Program issued a draft guidance outlining an enforcement policy for the FSMA final rule on Requirements for Additional Traceability Records for Certain Foods. The agency states it currently does not intend to enforce certain traceability requirements for specific retail food establishments and restaurants.

Other Food
Source ↗
Recall
1,3-Dimethylamylamine (DMAA)

Leader Formulas, LLC. Issues Voluntary Nationwide Recall of RAPTURE Preworkout Due to the Presence of 1,3-Dimethylamylamine (DMAA)

Leader Formulas, LLC. has initiated a voluntary nationwide recall of one lot of RAPTURE Preworkout dietary supplement powder (Lot 260327-4) due to the presence of 1,3-Dimethylamylamine (DMAA). DMAA is associated with serious cardiovascular risks, including heart attack and elevated blood pressure. The product was distributed nationwide through retail stores and the company's website.

Sports Performance
Source ↗
Safety Alert
particulate matterPVC

IV Tubing Set Correction: ICU Medical Updates Use Instructions for IV Tubing Sets

ICU Medical has issued a Class II recall for several types of IV tubing sets, including Plum, Gravity, and Oncology administration sets, due to the presence of black specks and particulate matter in the drip chambers. A subsequent investigation by the company and the FDA determined that the discoloration is intrinsic to the PVC material and does not enter the fluid path or pose a safety risk to patients. While product returns are not required, healthcare providers are instructed to inspect devices before use and segregate any units containing loose particulate matter.

Class Ii Devices
Source ↗

Don't miss the next briefing.

The weekly FDA digest for product teams. Free. No account required.

No spam. Unsubscribe anytime.

WHO IT'S FOR

You don't have a regulatory team.
You have Policy Canary.

Whether you're the founder, the quality lead, or the person who gets the call when something goes wrong — you need product-level answers, not regulatory summaries.

Founder / CEO

32 SKUs · 40+ active ingredients

“Which of my 32 SKUs is affected? I can’t cross-reference 40+ ingredients manually after every FDA notice.”

QA Manager

Moisturizer line · Next audit: Q2 2026

“Does the new BHA guidance apply to our moisturizer line? I need to know before our next audit.”

Product Manager

Q3 launch timeline · Collagen SKU at risk

“What does this collagen identity testing warning mean for our Q3 launch timeline?”

VP Regulatory

47 products · 3 categories

“I have 47 products. Show me which ones are affected — not a 500-page Federal Register summary.”

Don't find out from a recall notice.

Your Marine Collagen Powder. Your BHA Eye Cream. Monitored by name, matched by ingredient, matched against every FDA change.

Your products monitored by name and ingredient

Action items with deadlines, not summaries

Every claim linked to the source document

All-clear confirmation when nothing affects you

The FDA cut 3,859 employees. Enforcement is less predictable, not more.

7

FDA data sources

<24 hrs

pub to email

169K

substances indexed

How many products?

5

Monthly Cost

$99

Included Products

5

Base Plan

Total: $99/mo

Includes 5 products

Full access included. No data caps. Cancel anytime.